Clinical trial
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
NCT00412984 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00412984 |
|---|---|
| Title | Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation |
| Official title | A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation |
| Acronym | ARISTOTLE |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation, Atrial Flutter |
| Intervention type | Drug |
| Interventions | warfarin, apixaban |
| Enrollment | 20,976 |
| Start date | Dec 31, 2006 |
| Primary completion | May 25, 2011 |
| Completion | May 25, 2011 |
| First posted | Dec 19, 2006 |
| Last update posted | Jul 3, 2018 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, Finland and 29 more |
At a glance
- 1,000+ Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: